Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. Resistance to EGFR inhibitors is frequently associated with enhanced vascular endothelial growth factor (VEGF) levels. This multi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Mol Biosci
Hauptverfasser: Yang, Xue, Xia, Yang, Xu, Liyan, Liang, Li, Zhuo, Minglei, Wu, Meina, An, Tongtong, Wang, Ziping, Wang, Yuyan, Li, Jianjie, Zhong, Jia, Chen, Hanxiao, Jia, Bo, Wang, Jingjing, Zhao, Jun
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2021
Schlagworte:
Molecular Biosciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8131525/
https://ncbi.nlm.nih.gov/pubmed/34026823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmolb.2021.639892
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge